Developer docs
API playgroundTry for free, no card

Search company profiles

Mylab Discovery Solutions

Full company profile

uuid0002ull

Namestring
Mylab Discovery Solutions
Legal namestring
Mylab Discovery Solutions Limited
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Mylab Discovery Solutions Limited is an India-based in-vitro diagnostics company founded in 2016 and headquartered in Lonavla, operating with a small employee base of 11-50 staff. The company develops and manufactures rapid point-of-care diagnostic test kits, with two core commercial products: a pair of rapid dengue detection tests launched in August 2023 that deliver results in 15-20 minutes without laboratory infrastructure, and the PregaScreen home pregnancy test launched on June 10, 2025 for the direct-to-consumer retail market. Its underlying technology centers on rapid lateral-flow assay platforms targeting decentralized and home-based testing use cases.

The company generates revenue primarily through hardware sales of its diagnostic test kits, distributed via two distinct channels: point-of-care channels serving healthcare providers and clinical settings (for dengue and other professional-use kits), and retail/physical storefront channels targeting individual consumers for at-home self-testing products. Pricing is not publicly disclosed, and no enterprise customer logos, contract structures, or recurring revenue streams are evidenced in available data. In June 2023, Mylab secured a strategic minority investment of ₹106 crore (approximately $12.9M USD) from Zydus Lifesciences via its subsidiary Zydus Animal Health & Investments, which acquired a 6.5% equity stake and is positioned as a distribution and research partner for decentralized healthcare solutions in India. The company also acquired Sanskritech Smart Solutions in September 2021 for an undisclosed sum, and its primary historical investor appears to be Rising Sun Holdings. Mylab operates exclusively in the Indian domestic market, with no international footprint claimed, and its core customer segments span healthcare providers, clinical settings, and consumer self-testers.

Short descriptiontext

Mylab Discovery Solutions is an India-based in-vitro diagnostics company that develops rapid point-of-care test kits, including dengue detection tests and the PregaScreen home pregnancy test, serving healthcare providers, clinical settings, and retail consumers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLonavala, India
HQ citystring
Lonavala
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
in-vitro diagnostics, rapid diagnostic tests, point-of-care testing, home pregnancy tests, dengue detection kits
Industry1 code
PRIMARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
In-vitro Diagnostics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1In-vitro Diagnostics Products
TypeHardware Sales
Description

Mylab generates revenue through the sale of in-vitro diagnostic products including rapid test kits for dengue detection and home pregnancy tests. The company operates in the diagnostics sector providing products for both professional use and consumer self-testing.

biospectrumindia.com
Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Technology or R&D, Supply Chain, Personnel, Marketing or Sales
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1PregaScreen
Description

Home pregnancy test launched by Mylab Discovery Solutions

market.us
+1 more record
Core offering1 text field

Mylab Discovery Solutions Limited is an in-vitro diagnostics manufacturer that develops and produces rapid diagnostic test kits. Its portfolio includes rapid dengue detection tests intended for healthcare/clinical use and the PregaScreen home pregnancy test intended for consumer self-testing. Both product lines are designed to deliver results in approximately 15-20 minutes without requiring laboratory infrastructure.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Results delivered in 15-20 minutes for dengue detection tests
Product overview1 text field

Mylab Discovery Solutions is an India-based in-vitro diagnostics company that develops and manufactures rapid diagnostic tests. The company offers a portfolio of point-of-care testing products including the PregaScreen home pregnancy test and rapid dengue detection tests. The products are designed for decentralized testing, enabling users to obtain results at home or in clinical settings without laboratory infrastructure.

Product and service2 records
1PregaScreen Home Pregnancy Test
CategoryHome Pregnancy Testing
Description

An at-home rapid pregnancy test kit designed for individual consumer self-testing, delivering results in approximately 15-20 minutes without requiring laboratory infrastructure.

2Rapid Dengue Detection Test
CategoryIn-vitro Diagnostics / Infectious Disease Testing
Description

A rapid in-vitro diagnostic test kit for dengue pathogen detection, designed for healthcare providers and clinical point-of-care use, producing results in approximately 15-20 minutes without laboratory processing.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

India-based molecular and rapid diagnostics manufacturer with a Truenat platform deployed across point-of-care settings. Direct comp to Mylab in the Indian IVD manufacturing space serving decentralized healthcare.

TypeBroad incumbent
Description

One of India's largest IVD players with a wide portfolio of reagents and diagnostic instruments across clinical chemistry, immunoassays, and rapid tests. Compares to Mylab as an Indian IVD manufacturer serving clinical laboratories.

3J. Mitra & Co.
TypeDirect peer
Description

India-based diagnostics manufacturer specializing in ELISA, rapid test kits, and blood screening reagents. Directly comparable product portfolio to Mylab's rapid IVD test kits.

4Tulip Group
TypeDirect peer
Description

Indian diagnostics company focused on rapid immunodiagnostic test kits and pregnancy tests, including branded consumer products. Directly competitive with Mylab in rapid tests and home pregnancy test categories.

TypeBroad incumbent
Description

Korean IVD manufacturer with a wide portfolio of rapid diagnostic test kits (including COVID-19 antigen, dengue, pregnancy) sold globally. Comparable product mix to Mylab with strong rapid-test franchise.

TypeBroad incumbent
Description

India-headquartered medical technology company with broad IVD and medical device portfolio covering immunoassay, hematology, and rapid diagnostics. Comparable breadth and India presence to Mylab.

7HiMedia Laboratories
TypeDirect peer
Description

India-based manufacturer of microbiology, diagnostics, and life science products, including rapid test kits. Comparable Indian IVD manufacturer with reagent and kit offerings similar to Mylab.

8Agappe Diagnostics
TypeDirect peer
Description

Indian IVD company offering reagents, rapid test kits, and instruments across clinical chemistry and immunodiagnostics. Comparable product strategy and India market focus to Mylab.

9Abbott (Diagnostics)
TypeBroad incumbent
Description

Global IVD giant with rapid test products including Panbio dengue and pregnancy tests. Comparable core categories to Mylab, though Abbott operates globally across a much broader portfolio.

TypeRegional player
Description

India-based diagnostics manufacturer with portfolio of rapid test kits and immunoassay products. Similar manufacturing base and product overlap with Mylab within India.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mylab Discovery Solutions

In-vitro Diagnosticsmylabdiscoverysolutions.com

Mylab Discovery Solutions is an India-based in-vitro diagnostics company that develops rapid point-of-care test kits, including dengue detection tests and the PregaScreen home pregnancy test, serving healthcare providers, clinical settings, and retail consumers.

What Mylab Discovery Solutions does

Mylab Discovery Solutions Limited is an India-based in-vitro diagnostics company founded in 2016 and headquartered in Lonavla, operating with a small employee base of 11-50 staff. The company develops and manufactures rapid point-of-care diagnostic test kits, with two core commercial products: a pair of rapid dengue detection tests launched in August 2023 that deliver results in 15-20 minutes without laboratory infrastructure, and the PregaScreen home pregnancy test launched on June 10, 2025 for the direct-to-consumer retail market. Its underlying technology centers on rapid lateral-flow assay platforms targeting decentralized and home-based testing use cases.

The company generates revenue primarily through hardware sales of its diagnostic test kits, distributed via two distinct channels: point-of-care channels serving healthcare providers and clinical settings (for dengue and other professional-use kits), and retail/physical storefront channels targeting individual consumers for at-home self-testing products. Pricing is not publicly disclosed, and no enterprise customer logos, contract structures, or recurring revenue streams are evidenced in available data. In June 2023, Mylab secured a strategic minority investment of ₹106 crore (approximately $12.9M USD) from Zydus Lifesciences via its subsidiary Zydus Animal Health & Investments, which acquired a 6.5% equity stake and is positioned as a distribution and research partner for decentralized healthcare solutions in India. The company also acquired Sanskritech Smart Solutions in September 2021 for an undisclosed sum, and its primary historical investor appears to be Rising Sun Holdings. Mylab operates exclusively in the Indian domestic market, with no international footprint claimed, and its core customer segments span healthcare providers, clinical settings, and consumer self-testers.

Mylab Discovery Solutions firmographics

Firmographics
Name
Mylab Discovery Solutions
Legal name
Mylab Discovery Solutions Limited
Website
https://mylabdiscoverysolutions.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
101–250 employees
Short description
Mylab Discovery Solutions is an India-based in-vitro diagnostics company that develops rapid point-of-care test kits, including dengue detection tests and the PregaScreen home pregnancy test, serving healthcare providers, clinical settings, and retail consumers.
Ownership category
akta.pro rank

Mylab Discovery Solutions industry classification

Industry
Product category
In-vitro Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • In-vitro diagnostics
  • Rapid diagnostic tests
  • Point-of-care testing
  • Home pregnancy tests
  • Dengue detection kits

Where Mylab Discovery Solutions is headquartered

Location

Headquarters

HQ city
Lonavala
HQ country
India
HQ region
Asia

Markets served

Mylab Discovery Solutions business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Operations, Technology or R&D, Supply Chain, Personnel, Marketing or Sales

Revenue model

  1. In-vitro Diagnostics Products: Mylab generates revenue through the sale of in-vitro diagnostic products including rapid test kits for dengue detection and home pregnancy tests. The company operates in the diagnostics sector providing products for both professional use and consumer self-testing.

Go-to-market motion1 record

Distribution channels2 records

Mylab Discovery Solutions product offering

Product offering

Core offering

Mylab Discovery Solutions Limited is an in-vitro diagnostics manufacturer that develops and produces rapid diagnostic test kits. Its portfolio includes rapid dengue detection tests intended for healthcare/clinical use and the PregaScreen home pregnancy test intended for consumer self-testing. Both product lines are designed to deliver results in approximately 15-20 minutes without requiring laboratory infrastructure.

Product overview

Mylab Discovery Solutions is an India-based in-vitro diagnostics company that develops and manufactures rapid diagnostic tests. The company offers a portfolio of point-of-care testing products including the PregaScreen home pregnancy test and rapid dengue detection tests. The products are designed for decentralized testing, enabling users to obtain results at home or in clinical settings without laboratory infrastructure.

Differentiator

Problem solved

Functional benefit

Brands

  • PregaScreen: Home pregnancy test launched by Mylab Discovery Solutions
  • Rapid Dengue Detection Tests

Products and services

  • PregaScreen Home Pregnancy Test An at-home rapid pregnancy test kit designed for individual consumer self-testing, delivering results in approximately 15-20 minutes without requiring laboratory infrastructure.
  • Rapid Dengue Detection Test A rapid in-vitro diagnostic test kit for dengue pathogen detection, designed for healthcare providers and clinical point-of-care use, producing results in approximately 15-20 minutes without laboratory processing.

Quantifiable outcome

  • Results delivered in 15-20 minutes for dengue detection tests

Companies that use Mylab Discovery Solutions

Customer profile

Segments3 records

Ideal customer profiles2 records

Mylab Discovery Solutions technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Mylab Discovery Solutions partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Mylab Discovery Solutions competitors and assessment

Company assessment

Direct peers

  • Molbio Diagnostics: India-based molecular and rapid diagnostics manufacturer with a Truenat platform deployed across point-of-care settings. Direct comp to Mylab in the Indian IVD manufacturing space serving decentralized healthcare.
  • J. Mitra & Co. India-based diagnostics manufacturer specializing in ELISA, rapid test kits, and blood screening reagents. Directly comparable product portfolio to Mylab's rapid IVD test kits.
  • Tulip Group: Indian diagnostics company focused on rapid immunodiagnostic test kits and pregnancy tests, including branded consumer products. Directly competitive with Mylab in rapid tests and home pregnancy test categories.
  • HiMedia Laboratories: India-based manufacturer of microbiology, diagnostics, and life science products, including rapid test kits. Comparable Indian IVD manufacturer with reagent and kit offerings similar to Mylab.
  • Agappe Diagnostics: Indian IVD company offering reagents, rapid test kits, and instruments across clinical chemistry and immunodiagnostics. Comparable product strategy and India market focus to Mylab.

Broad incumbents

  • Transasia Bio-Medicals: One of India's largest IVD players with a wide portfolio of reagents and diagnostic instruments across clinical chemistry, immunoassays, and rapid tests. Compares to Mylab as an Indian IVD manufacturer serving clinical laboratories.
  • SD Biosensor: Korean IVD manufacturer with a wide portfolio of rapid diagnostic test kits (including COVID-19 antigen, dengue, pregnancy) sold globally. Comparable product mix to Mylab with strong rapid-test franchise.
  • Trivitron Healthcare: India-headquartered medical technology company with broad IVD and medical device portfolio covering immunoassay, hematology, and rapid diagnostics. Comparable breadth and India presence to Mylab.
  • Abbott (Diagnostics): Global IVD giant with rapid test products including Panbio dengue and pregnancy tests. Comparable core categories to Mylab, though Abbott operates globally across a much broader portfolio.

Regional players

  • Bhat Bio-Tech India: India-based diagnostics manufacturer with portfolio of rapid test kits and immunoassay products. Similar manufacturing base and product overlap with Mylab within India.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Mylab Discovery Solutions social profiles

Digital presence

Mylab Discovery Solutions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mylab Discovery Solutions leadership team

Management profile

Number of profiles

Profiles2 records

Mylab Discovery Solutions funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mylab Discovery Solutions M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mylab Discovery Solutions

What does Mylab Discovery Solutions do?

Mylab Discovery Solutions Limited is an in-vitro diagnostics manufacturer that develops and produces rapid diagnostic test kits. Its portfolio includes rapid dengue detection tests intended for healthcare/clinical use and the PregaScreen home pregnancy test intended for consumer self-testing. Both product lines are designed to deliver results in approximately 15-20 minutes without requiring laboratory infrastructure.

Is Mylab Discovery Solutions a public or private company?

Mylab Discovery Solutions is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Mylab Discovery Solutions founded?

Mylab Discovery Solutions was founded in 2016. It employs 101 to 250 people.

Where is Mylab Discovery Solutions based?

Mylab Discovery Solutions is headquartered in Lonavala, India, in the Asia region.

How does Mylab Discovery Solutions make money?

One revenue line is on record: in-vitro Diagnostics Products.

Who are Mylab Discovery Solutions's main competitors?

Direct peers on record are Molbio Diagnostics, J. Mitra & Co., Tulip Group, HiMedia Laboratories and Agappe Diagnostics. Broad incumbents are Transasia Bio-Medicals, SD Biosensor, Trivitron Healthcare and Abbott (Diagnostics). Bhat Bio-Tech India is listed as a regional player.

Does Mylab Discovery Solutions have an API?

No public API is recorded for Mylab Discovery Solutions.

What industry is Mylab Discovery Solutions in?

Mylab Discovery Solutions's product category is In-vitro Diagnostics. Its primary akta.pro industry code is HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comEmerging Growth Patterns Driving Expansion in the Paper Diagnostics MarketThe paper diagnostics market is projected to reach $17.31 billion by 2030, growing at a compound annual growth rate of 10.5%, driven by demand for home-based diagnostics, point-of-care testing, and paper microfluidics advancements. In March 2023, French pharmaceutical group Servier partnered with Germany's QIAGEN to co-develop a companion diagnostic test for IDH1 mutations in acute myeloid leukemia patients, based on positive Phase 3 AGILE study results. In August 2023, India-based Mylab Discovery Solutions launched two rapid dengue detection tests providing results in 15-20 minutes without laboratory requirements.Market ScoopAt-Home Pregnancy Testing MarketThe global at-home pregnancy testing market was valued at US$ 0.8 billion in 2024 and is projected to reach US$ 1.2 billion by 2034, growing at a CAGR of 4.5% during the forecast period. North America led the market with a 40.3% share in 2024, while the line indicator product type segment held 64.3% of the market and retail sales captured 78.4% of distribution channel share. Prega News expanded its product portfolio in India on April 23, 2025, and Mylab Discovery Solutions launched its PregaScreen home pregnancy test on June 10, 2025, marking new entries in the competitive landscape.GenomeWebGates Foundation Awards Multiple Dx, Omics Grants in August and SeptemberThe Bill & Melinda Gates Foundation awarded over 500 new grants in August and September, with a selection of notable awards directed toward diagnostic and omics projects. Recipients include institutions such as Imperial College London, Mylab, and the Task Force for Global Health, which received funding to develop surveillance tools, affordable diagnostics, and validate assays for diseases like HIV, tuberculosis, malaria, and mpox. These initiatives focus on strengthening public health infrastructure and disease detection capabilities in low- and middle-income countries.The HinduZydus arm acquiring 6.5% stake in Mylab Discovery Solutions for ₹106 croreZydus Lifesciences is acquiring a 6.5% equity stake in Mylab Discovery Solutions for ₹106 crore through a share purchase agreement with Rising Sun Holdings and the target company. This investment aims to expand Zydus's presence in the diagnostics sector, particularly in point-of-care testing devices. Mylab, which reported a turnover of ₹95 crore in the fiscal year ended March, specializes in the research, development, and manufacturing of in-vitro diagnostics kits and related products.BusinessLineZydus Lifesciences picks up equity in Mylab Discovery Solutions for ₹106 croreZydus Lifesciences acquired a 6.5% equity stake in Mylab Discovery Solutions for ₹106 crore through its subsidiary Zydus Animal Health & Investments Limited. The investment aims to combine Zydus's therapeutic capabilities with Mylab's diagnostic expertise to develop decentralized healthcare solutions and advance precision medicine.BioSpectrum IndiaZydus acquires 6.5% stake in Mylab for Rs 106 CrZydus Animal Health and Investments, a subsidiary of Zydus Lifesciences, acquired a 6.5% stake in diagnostics company Mylab Discovery Solutions for Rs 106 crore. The transaction involves purchasing shares from Rising Sun Holdings and Mylab itself, with the final share count potentially adjusting based on Mylab's financial performance by March 2024. This investment is intended to help Zydus expand its presence in the growing in-vitro diagnostics market.MintZydus Life to acquire equity stake in Mylab Discovery for ₹106 crore | Company Business NewsZydus Lifesciences announced the acquisition of a 6.5% equity stake in Mylab Discovery Solutions for ₹106 crore through its subsidiary, Zydus Animal Health and Investments. The transaction involves the purchase of 65,06,500 equity shares from Rising Sun Holdings and is structured with potential adjustments based on Mylab's financial performance for the year ending March 31, 2024. This investment aims to help Zydus participate in the growing diagnostics space characterized by increased penetration of point-of-care testing devices.Business Wire BlogDnaNudge Forges Strategic Partnership With Mylab Discovery Solutions to Deliver Next-Generation Point-of-Decision Diagnostics for Diabetic Foot InfectionsDnaNudge and Mylab Discovery Solutions signed an MoU to develop molecular diagnostics for diabetic foot infections, with a detection kit expected in India in Q2 2023. The kit aims to identify bacteria and reduce risks of amputation and antimicrobial resistance, which caused 1.27 million deaths in 2019.BusinessLineMylab sets up advanced genetic laboratory and cancer research centre for MUHSMylab Discovery Solutions inaugurated a genetic laboratory and cancer research centre at Maharashtra University of Health Sciences in Pune, with Governor Bhagat Singh Koshyari. The facility offers DNA, RNA, chromosome, and protein testing for diagnosing congenital, prenatal, hematologic, and oncologic disorders.